Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 1/20 | 0.39 |
| ▸ | WNT3A | P56704 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18975507 | 0.84 | NR4A2 (0.42) | CTNNB1WNT3ANR4A2JAK3 | |
| SCHEMBL18975247 | 0.84 | NR4A2 (0.39) | NR4A2 | |
| SCHEMBL18975206 | 0.84 | NR4A2 (0.56) | NR4A2 | |
| SCHEMBL18975235 | 0.79 | JAK2 (0.37) | JAK3 | |
| SCHEMBL18975462 | 0.78 | JAK3 (0.33) | JAK3 | |
| SCHEMBL18975204 | 0.78 | JAK3 (0.37) | JAK3 | |
| SCHEMBL18975215 | 0.78 | JAK3 (0.34) | JAK3 | |
| SCHEMBL18974985 | 0.76 | MTNR1A (0.36) | — | |
| SCHEMBL18975053 | 0.76 | KCNH2 (0.41) | NR4A2JAK3 | |
| SCHEMBL18975231 | 0.76 | JAK3 (0.38) | JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166561-A1 | QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | ALPHARMAGEN LLC (US) | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166561-A1 | QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | CHRNA7, CHRNA2, CHRNA6 | CTNNB1 3703/4885WNT3A 2246/4885KDM4E 3528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.